ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

A bird's eye view is now demanded in the area of cancer research to suppress the suffering
of cancer patient and mediate the lack of treatment related to chemotherapy. Chemotherapy …

Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a
small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports …

Identification of targeted therapies for TNBC is an urgent medical need. Using a drug
combination screen reliant on synthetic lethal interactions, we identified clinically relevant …

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer
characterized by genomic and transcriptional heterogeneity and exhibiting aggressive …

The cellular transport process of DNA is hampered by cell membrane barriers, and hence, a
delivery vehicle is essential for realizing the potential benefits of gene therapy to combat a …

Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …